Brevan Howard Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Brevan Howard Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.67M	Buy	88,596 +17,183	+24%	+$706K	0.04%	251
2025 Q4	$2.89M	Buy	+71,413	New	+$1.65M	0.03%	364
2024 Q4	–	Sell	-15,682	Closed	-$131K	–	1429
2024 Q3	$131K	Buy	+15,682	New	+$129K	﹤0.01%	1054
2024 Q1	–	Sell	-10,842	Closed	-$70.4K	–	1345
2023 Q4	$70.4K	Buy	+10,842	New	+$57.3K	﹤0.01%	981

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Brevan Howard Capital Management's TERN Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Terns Pharmaceuticals (TERN) stake by 24% in Q1 2026, buying an estimated $706K and bringing the position to 88,596 shares worth $4.67M. The position accounts for 0.04% of the portfolio, ranked #251.

Brevan Howard Capital Management first reported a position in TERN in Q4 2023 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Brevan Howard Capital Management held 88,596 shares of Terns Pharmaceuticals worth $4.67M as of Q1 2026.
Brevan Howard Capital Management bought 17,183 Terns Pharmaceuticals shares in Q1 2026, an estimated $706K.
Terns Pharmaceuticals made up 0.04% of Brevan Howard Capital Management's portfolio in Q1 2026, its #251 holding.
Brevan Howard Capital Management first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.